Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?

Autor: Soytas M; Division of Urology, Department of Surgery, McGill University, Montréal, Quebec, Canada., Dragomir A; Division of Urology, Department of Surgery, McGill University, Montréal, Quebec, Canada., Sawaya GB; Department of Surgery, Faculty of Medicine and Health Sciences, McGill University, Montréal, Quebec, Canada., Hesswani C; Division of Urology, Department of Surgery, McGill University, Montréal, Quebec, Canada., Tanguay M; Division of Urology, Department of Surgery, McGill University, Montréal, Quebec, Canada., Finelli A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Wood L; Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, Nova Scotia, Canada., Rendon R; Division of Urology, Dalhousie University, Halifax, Nova Scotia, Canada., Bansal R; Division of Urology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada., Lalani AK; Division of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada., Heng DYC; Division of Oncology, University of Calgary, Calgary, Alberta, Canada., Bhindi B; Division of Urology, University of Calgary, Calgary, Alberta, Canada., Basappa NS; Division of Medical Oncology, Alberta Health Services, Edmonton, Alberta, Canada., Dean L; Division of Urology, Alberta Health Services, Edmonton, Alberta, Canada., So A; Department of Urologic Sciences, University of British Colombia, Vancouver, British Columbia, Canada., Nayak JG; Section of Urology, University of Manitoba, Winnipeg, Manitoba, Canada., Bjarnason G; Division of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada., Breau R; Division of Urology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada., Lavallee L; Division of Urology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada., Lattouf JB; Division of Urology, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada., Pouliot F; Division of Urology, Université Laval, Montréal, Quebec, Canada., Bonert M; Division of Anatomical Pathology, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, Ontario, Canada., Tanguay S; Division of Urology, Department of Surgery, McGill University, Montréal, Quebec, Canada.

Publikováno v: BJU international [BJU Int] 2024 Dec 04. Date of Electronic Publication: 2024 Dec 04.

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma

Autor: MacKenzie, M.J. ^*, Rini, B.I., Elson, P., Schwandt, A., Wood, L., Trinkhaus, M., Bjarnason, G., Knox, J.

Publikováno v: In Annals of Oncology January 2011 22(1):145-148

Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population.

Autor: Millan B; Division of Urology, McMaster Institute of Urology, McMaster University, Hamilton, Ontario, Canada. Electronic address: braden.millan@medportal.ca., Breau RH; Division of Urology, University of Ottawa, Ottawa, Ontario, Canada., Mallick R; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada., Wood L; Division of Medical Oncology, QEII Health Sciences Center, Halifax, Nova Scotia, Canada., Rendon R; Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada., Finelli A; Division of Urology, University of Toronto, Toronto, Ontario, Canada., So AI; Department of Urologic Sciences, The University of British Columbia, Vancouver, British Columbia, Canada., Lavallée LT; Division of Urology, University of Ottawa, Ottawa, Ontario, Canada., Pouliot F; Division of Urology, CHU of Québec and Laval University, Montreal, Quebec, Canada., Bhindi B; Division of Urology, University of Calgary, Calgary, Alberta, Canada., Heng D; Division of Medical Oncology, University of Calgary, Calgary, Alberta, Canada., Drachenberg D; Division of Urology, University of Manitoba, Winnipeg, Manitoba, Canada., Tanguay S; Department of Surgery, McGill University, Montreal, Quebec, Canada., Dean L; Department of Surgery, Alberta Urology Institute Research Center, University of Alberta, Edmonton, Alberta, Canada., Basappa NS; Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta. Edmonton, Canada., Lattouf JB; Department of Surgery, University of Montreal, Montreal, Quebec, Canada., Bjarnason G; Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Lalani AK; Division of Medical Oncology, McMaster University, Hamilton, Ontario, Canada., Kapoor A; Division of Urology, McMaster Institute of Urology, McMaster University, Hamilton, Ontario, Canada.

Publikováno v: Urologic oncology [Urol Oncol] 2023 Jul; Vol. 41 (7), pp. 328.e15-328.e23. Date of Electronic Publication: 2023 May 16.

Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers.

Autor: Dragomir A; McGill University, Montreal, Canada. Electronic address: alice.dragomir@mcgill.ca., Nazha S; McGill University, Montreal, Canada., Tanguay S; McGill University, Montreal, Canada., Breau RH; The Ottawa Hospital, Ottawa, Canada., Bhindi B; Southern Alberta Institute of Urology, Alberta, Canada., Rendon RA; Queen Elizabeth II Health Sciences Centre, Halifax, Canada., Kapoor A; Juravinski Cancer Centre, McMaster University, Hamilton, Canada., Hotte SJ; Juravinski Cancer Centre, McMaster University, Hamilton, Canada., Basappa N; Cross Cancer Institute, University of Alberta, Edmonton, Canada., Fairey A; Cross Cancer Institute, University of Alberta, Edmonton, Canada., So AI; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada., Kollmannsberger C; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada., Finelli A; Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada., Hansen A; Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada., Canil C; The Ottawa Hospital, Ottawa, Canada., Heng D; Tom Baker Cancer Centre, University of Calgary, Calgary, Canada., Lattouf JB; Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, Canada., Bjarnason G; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada., Power N; Western University, London, Canada., Pouliot F; Centre Hospitalier Universitaire de Québec, University of Laval, Quebec, Canada., Wood LA; Queen Elizabeth II Health Sciences Centre, Halifax, Canada.

Publikováno v: European urology focus [Eur Urol Focus] 2022 Nov; Vol. 8 (6), pp. 1703-1710. Date of Electronic Publication: 2021 Nov 01.

Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).

Autor: Patel JN; Department of Cancer Pharmacology and Pharmacogenomics, Levine Cancer Institute, Atrium Health, Charlotte., Jiang C; Alliance Statistics and Data Center., Owzar K; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina., Mulkey F; Alliance Statistics and Data Center., Luzum JA; Department of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan., Mamon HJ; Department of Radiation Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts., Haller DG; Department of Gastrointestinal Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Dragovich T; Department of Hematology/Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona., Alberts SR; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Bjarnason G; Department of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada., Willet CG; Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina., Niedzwiecki D; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina., Enzinger P; Department of Radiation Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts., Ratain MJ; Center for Personalized Therapeutics, University of Chicago, Chicago, Illinois., Fuchs C; Department of Medical Oncology, Smilow Cancer Hospital, Yale University, New Haven, Connecticut., McLeod HL; Department of Precision Medicine, USF Taneja College of Pharmacy and the Geriatric Oncology Consortium, Tampa, Florida, USA.

Publikováno v: Pharmacogenetics and genomics [Pharmacogenet Genomics] 2021 Dec 01; Vol. 31 (9), pp. 215-220.